CLOBAZAM (clobazam) by Teva is cytochrome p450 2d6 inhibitors [moa]. First approved in 2018.
Drug data last refreshed 18h ago
Cytochrome P450 2D6 Inhibitors
Benzodiazepine
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy
Worked on CLOBAZAM at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.